Evenamide
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
|
|
| CAS Number | 1092977-61-1  |
| PubChem (CID) | 25105689 |
| ChemSpider | 44208827 |
| UNII | ON5S6N53JS |
| Chemical and physical data | |
| Formula | C16H26N2O2 |
| Molar mass | 278.38984 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, that is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[1]
See also[edit]
References[edit]
- ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
- ^ Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
- ^ a b Satya Prakash Gupta (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
- ^ Zuliani, Valentina; Amori, Laura; Rivara, Mirko (2011). "Advances in Design and Development of Sodium Channel Blockers": 79–115. doi:10.1007/978-3-642-19922-6_4.
External links[edit]
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
